Sanofi stock: Scribe and Novavax deals widen R&D toolkit

Sanofi's research strategy gained a new angle on Friday, November 13, 2026, after Yahoo Finance reported an expanded collaboration with Scribe Therapeutics and a milestone payment to Novavax linked to a combined influenza and COVID-19 vaccine trial.

Sanofi and Scribe expanded their collaboration to give Sanofi access to Scribe's ELXR epigenetic silencing platform. The agreement adds gene-editing and epigenetic tools to Sanofi's early-stage therapeutic research programs, without representing a marketed product or a late-stage approval.

Pipeline renewal remains the focus

The Scribe arrangement supports Sanofi's effort to refresh its research pipeline through external platforms. Its investment case will depend on whether these tools produce candidates that advance through clinical development and ultimately reach commercial markets.

The separate Novavax development concerns a Phase III trial of a combined influenza and COVID-19 vaccine. Progress in the program triggered a milestone payment to Novavax, linking Sanofi's partnership strategy to a next-generation vaccine opportunity.

Course moves since the prior report

Sanofi stock traded at 87.68 euros on Lang & Schwarz at 18:31:38 CET on Friday, November 13, 2026. That was 1.89 percent above the 86.05-euro quote in the relevant report published on Wednesday, November 11. This change since that report is separate from a daily Xetra comparison.

For investors, the developments broaden Sanofi's research options but do not yet add a marketed product or late-stage approval. The next material question is whether the partnerships can deliver clinical assets capable of supporting growth beyond the company's established immunology franchise.

Investors can follow the broader French market context in Current market reports.

More news and analyses on Sanofi stock.